Nanotechnology in brain targeting

Katerina Lalatsa; Diana Moreira Leite; Melina Fernandes Figueiredo; Max O'Connor

doi:10.1016/B978-0-12-812218-1.00005-1

Nanotechnology in brain targeting

Katerina Lalatsa, Diana Moreira Leite, Melina Fernandes Figueiredo, Max O'Connor

Institute of Life Sciences and Healthcare

Research output: Chapter in Book/Report/Conference proceeding › Chapter (peer-reviewed) › peer-review

Abstract

Patients suffering from malignant brain tumours have an extremely poor prognosis (shorter than 15 months) irrespectively of improvements in surgergy, tumour imaging and therapeutic protocols. Brain tumour treatment has been principally hampered by poor permeability of drugs/therapeutics across the blood-brain barrier (BBB). Nanotechnology enabled treatments have shown unique promise in delivering drugs and macromolecules across the BBB and offer unique abilities in targeting tumour cells exploiting tumour biology, while also improving the pharmacokinetic profile of drugs and reducing off-target side-effects. In this chapter, we focus on the efficacy and safety of developed nano-enabled therapies that are currently under research for the treatment of brain tumours.

Original language	English
Title of host publication	Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors
Editors	Prashant Kesharwani, Umesh Gupta
Publisher	Elsevier
Chapter	5
Pages	111-145
Number of pages	35
Edition	1st
ISBN (Electronic)	978-0128122495
ISBN (Print)	978-0128122181
DOIs	https://doi.org/10.1016/B978-0-12-812218-1.00005-1
Publication status	Published - 27 Apr 2018

Keywords

Nanomedicines
Drug conjugates
Dendrimers
Nucleic acid-based nanomedicines
Peptide-based nanomedicines
Polymeric nanoparticles
Liposomes
Glioblastoma Multiforme
Brain tumours

Access to Document

10.1016/B978-0-12-812218-1.00005-1

https://www.elsevier.com/books/nanotechnology-based-targeted-drug-delivery-systems-for-brain-tumors/kesharwani/978-0-12-812218-1

Cite this

@inbook{e0befa68089843898b0faf498ecdb449,

title = "Nanotechnology in brain targeting",

abstract = "Patients suffering from malignant brain tumours have an extremely poor prognosis (shorter than 15 months) irrespectively of improvements in surgergy, tumour imaging and therapeutic protocols. Brain tumour treatment has been principally hampered by poor permeability of drugs/therapeutics across the blood-brain barrier (BBB). Nanotechnology enabled treatments have shown unique promise in delivering drugs and macromolecules across the BBB and offer unique abilities in targeting tumour cells exploiting tumour biology, while also improving the pharmacokinetic profile of drugs and reducing off-target side-effects. In this chapter, we focus on the efficacy and safety of developed nano-enabled therapies that are currently under research for the treatment of brain tumours.",

keywords = "Nanomedicines, Drug conjugates, Dendrimers, Nucleic acid-based nanomedicines, Peptide-based nanomedicines, Polymeric nanoparticles, Liposomes, Glioblastoma Multiforme, Brain tumours",

author = "Katerina Lalatsa and {Moreira Leite}, Diana and {Fernandes Figueiredo}, Melina and Max O'Connor",

note = "anotechnology-based Targeted Drug Delivery Systems for Brain Tumors, 1st Edition, Elsevier Editors: Prashant Kesharwani, Umesh Gupta",

year = "2018",

month = apr,

day = "27",

doi = "10.1016/B978-0-12-812218-1.00005-1",

language = "English",

isbn = "978-0128122181 ",

pages = "111--145",

editor = "Prashant Kesharwani and Umesh Gupta",

booktitle = "Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors",

publisher = "Elsevier",

edition = "1st",

}

TY - CHAP

T1 - Nanotechnology in brain targeting

AU - Lalatsa, Katerina

AU - Moreira Leite, Diana

AU - Fernandes Figueiredo, Melina

AU - O'Connor, Max

N1 - anotechnology-based Targeted Drug Delivery Systems for Brain Tumors, 1st Edition, Elsevier Editors: Prashant Kesharwani, Umesh Gupta

PY - 2018/4/27

Y1 - 2018/4/27

N2 - Patients suffering from malignant brain tumours have an extremely poor prognosis (shorter than 15 months) irrespectively of improvements in surgergy, tumour imaging and therapeutic protocols. Brain tumour treatment has been principally hampered by poor permeability of drugs/therapeutics across the blood-brain barrier (BBB). Nanotechnology enabled treatments have shown unique promise in delivering drugs and macromolecules across the BBB and offer unique abilities in targeting tumour cells exploiting tumour biology, while also improving the pharmacokinetic profile of drugs and reducing off-target side-effects. In this chapter, we focus on the efficacy and safety of developed nano-enabled therapies that are currently under research for the treatment of brain tumours.

AB - Patients suffering from malignant brain tumours have an extremely poor prognosis (shorter than 15 months) irrespectively of improvements in surgergy, tumour imaging and therapeutic protocols. Brain tumour treatment has been principally hampered by poor permeability of drugs/therapeutics across the blood-brain barrier (BBB). Nanotechnology enabled treatments have shown unique promise in delivering drugs and macromolecules across the BBB and offer unique abilities in targeting tumour cells exploiting tumour biology, while also improving the pharmacokinetic profile of drugs and reducing off-target side-effects. In this chapter, we focus on the efficacy and safety of developed nano-enabled therapies that are currently under research for the treatment of brain tumours.

KW - Nanomedicines

KW - Drug conjugates

KW - Dendrimers

KW - Nucleic acid-based nanomedicines

KW - Peptide-based nanomedicines

KW - Polymeric nanoparticles

KW - Liposomes

KW - Glioblastoma Multiforme

KW - Brain tumours

U2 - 10.1016/B978-0-12-812218-1.00005-1

DO - 10.1016/B978-0-12-812218-1.00005-1

M3 - Chapter (peer-reviewed)

SN - 978-0128122181

SP - 111

EP - 145

BT - Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors

A2 - Kesharwani, Prashant

A2 - Gupta, Umesh

PB - Elsevier

ER -

Nanotechnology in brain targeting

Abstract

Keywords

Access to Document

Fingerprint

Cite this